Ubiquitin family members in the regulation of the tumor suppressor p53

Subcellular Biochemistry

Volumn 54, Issue , 2010, Pages 116-135

  Xirodimas, Dimitris P ^a   Scheffher, Martin ^b  

^a University of Konstanz ^*

^b UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIA;

PROTEASOME; PROTEIN P53; SUMO 1 PROTEIN; UBIQUITIN;

ANIMAL; GENETICS; HUMAN; METABOLISM; UBIQUITINATION;

ANIMALS; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; SUMO-1 PROTEIN; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN; UBIQUITINATION;

EID: 84873648741     PISSN: 03060225     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-6676-6_10     Document Type: Article

References (183)

1. Lane DP, Crawford LV. T antigen is bound to a host protein in SV40-transformed cells. Nature 1979: 278:261-3.
2. Linzer DI, Levine AJ. Characterization ofa54Kdalton cellular SV40tumorantigenpresentinSV40-transformed cells and uninfected embryonal carcinoma cells. Cell 1979: 17:43-52.
3. DeLeo AB, Jay G, Appella E et al. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci USA 1979: 76:2420-4.
4. Baker SJ, Fearon ER, Nigro JM et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989: 244:217-21.
5. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989: 57:1083-93.
6. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000: 408:307-10.
7. Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 2003: 13:49-58.
8. Scheffher M, Whitaker NJ. Human papillomavirus-induced carcinogenesis and the ubiquitin-proteasome system. Semin Cancer Biol 2003; 13:59-67.
9. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007; 8:275-83.
10. Kruse JP, GuW. Modes ofp53 regulation. Cell 2009; 137:609-22.
11. Vousden KH, Prives C. Blinded by the Light: The Growing Complexity ofp53. Cell 2009; 137:413-31.
12. Toledo F, Bardot B. Cancer: Three birds with one stone. Nature 2009; 460:466-7.
13. Vaseva AV, Moll UM. The mitochondrial p53 pathway. Biochim Biophys Acta 2009; 1787:414-20.
14. Bargonetti J, Friedman PN, Kern SE et al. Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell 1991; 65:1083-91.
15. Kern SE, Kinzler KW, Bruskin A et al. Identification of p53 as a sequence-specific DNA-binding protein. Science 1991; 252:1708-11.
16. Pavletich NP, Chambers KA, Pabo CO. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev 1993; 7:2556-64.
17. Cho Y, Gorina S, Jeffrey PD et al. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenicmutations. Science 1994; 265:346-55.
18. Lu H, Levine AJ. Human TAFII31 protein is a transcriptional coactivator of the p53 protein. Proc Natl Acad Sci USA 1995; 92:5154-8.
19. Thut CJ, Chen JL, Klemm R et al. p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. Science 1995; 267:100-4.
20. Xiao H, Pearson A, Coulombe B et al. Binding of basal transcription factor TFIIH to the acidic activation domains ofVP16 andp53. Mol Cell Biol 1994; 14:7013-24.
21. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997; 90:595-606.
22. Lill NL, Grossman SR, Ginsberg D et al. Binding and modulation of p53 by p300/CBP coactivators. Nature 1997; 387:823-7.
23. Hupp TR, Meek DW, Midgley CA et al. Regulation of the specific DNA binding function of p53. Cell 1992;71:875-86.
24. Lee W, Harvey TS, Yin Y et al. Solution structure of the tetrameric minimum transforming domain of p53. Nat Struct Biol 1994; 1:877-90.
25. Jeffrey PD, Gorina S, Pavletich NP. Crystal structure of the tetramerization domain of the p53 tumor suppressorat 1.7 angstroms. Science 1995; 267:1498-502.
26. Bourdon JC, Fernandes K, Murray-Zmijewski F et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev 2005; 19:2122-37.
27. Maltzman W, Czyzyk L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 1984; 4:1689-94.
28. Kastan MB, Onyekwere O, Sidransky D et al. Participation of p53 protein in the cellular response to DNA damage. CancerRes 1991; 51:6304-11.
29. Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 1993; 8:307-18.
30. Graeber TG, Peterson JF, Tsai M et al. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol 1994; 14:6264-77.
31. Linke SP, Clarkin KC, Di Leonardo A et al. A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev 1996; 10:934-47.
32. Reich NC, Oren M, Levine AJ. Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol Cell Biol 1983; 3:2143-50.
33. Hubbert NL, Sedman SA, Schiller JT. Human papillomavirus type 16 E6 increases the degradation rate of p53 inhumankeratinocytes. JVirol 1992; 66:6237-41.
34. Scheffner M, Werness BA, Huibregtse JM et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63:1129-36.
35. Chowdary DR, Dermody JJ, Jha KK et al. Accumulation of p53 in a mutant cell line defective in the ubiquitinpathway. Mol CellBiol 1994; 14:1997-2003.
36. Maki CG, Huibregtse JM, Howley PM. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res 1996; 56:2649-54.
37. Haupt Y, Maya R, Kazaz A et al. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387:296-9.
38. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387:299-303.
39. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997; 420:25-7.
40. Fang S, Jensen JP, Ludwig RL et al. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 2000; 275:8945-51.
41. Honda R, Yasuda H. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene 2000; 19:1473-6.
42. Jones SN, Roe AE, Donehower LA et al. Rescue of embryonic lethality in Mdm2-deficient mice by absence ofp53. Nature 1995; 378:206-8.
43. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion ofp53. Nature 1995; 378:203-6.
44. Francoz S, Froment P, Bogaerts S et al. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci USA 2006; 103:3232-7.
45. Grier JD, Xiong S, Elizondo-Fraire AC et al. Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4. Mol Cell Biol 2006; 26:192-8.
46. Marine JC, Francoz S, Maetens M et al. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ 2006; 13:927-34.
47. Xiong S, Van Pelt CS, Elizondo-Fraire AC et al. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc Natl Acad Sci USA 2006; 103:3226-31.
48. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006; 6:909-23.
49. Itahana K, Mao H, Jin A et al. Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell 2007; 12:355-66.
50. Kussie PH, Gorina S, Marechal V et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressortransactivationdomain. Science 1996; 274:948-53.
51. Bottger A, Bottger V, Garcia-Echeverria C et al. Molecular characterization of the hdm2-p53 interaction. J Mol Biol 1997; 269:744-56.
52. Bottger A, Bottger V, Sparks A et al. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr Biol 1997; 7:860-9.
53. Vassilev LT, Vu BT, Graves B et al. In vivo activation of the p53 pathway by small-molecule antagonists ofMDM2. Science 2004; 303:844-8.
54. Chi SW, Lee SH, Kim DH et al. Structural details on mdm2-p53 interaction. J Biol Chem 2005; 280:38795-802.
55. Momand J, Zambetti GP, Olson DC et al. The mdm-2 oncogene product forms a complex with the p53 proteinandinhibits p53-mediatedtransactivation. Cell 1992; 69:1237-45.
56. Oliner JD, Pietenpol JA, Thiagalingam S et al. Oncoprotein MDM2 conceals the activation domain of tumour suppressorp53. Nature 1993; 362:857-60.
57. Saville MK, Sparks A, Xirodimas DP et al. Regulation of p53 by the ubiquitin-conjugating enzymes UbcH5B/C in vivo. J Biol Chem 2004; 279:42169-81.
58. Linares LK, Hengstermann A, Ciechanover A et al. HdmX stimulates Hdm2-mediated ubiquitination and degradation ofp53. Proc Natl Acad Sci USA 2003; 100:12009-14.
59. Grossman SR, Deato ME, Brignone C et al. Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 2003; 300:342-4.
60. Glockzin S, Ogi FX, Hengstermann A et al. Involvement of the DNA repair protein hHR23 in p53 degradation. Mol Cell Biol 2003; 23:8960-9.
61. Brignone C, Bradley KE, Kisselev AF et al. A post-ubiquitination role for MDM2 andhHR23A in the p53 degradationpathway. Oncogene 2004; 23:4121-9.
62. Kaur M, Pop M, Shi D et al. hHR23B is required for genotoxic-specific activation of p53 and apoptosis. Oncogene 2006; 26:1231-7.
63. Nakamura S, Roth JA, Mukhopadhyay T. Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination. Mol Cell Biol 2000; 20:9391-8.
64. Rodriguez MS, Desterro JM, Lain S et al. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol Cell Biol 2000; 20:8458-67.
65. Feng L, Lin T, Uranishi H et al. Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol Cell Biol 2005; 25:5389-95.
66. Krummel KA, Lee CJ, Toledo F et al. The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation. Proc Natl Acad Sci USA 2005; 102:10188-93.
67. Chan WM, Mak MC, Fung TK et al. Ubiquitination of p53 at multiple sites in the DNA-binding domain. Mol Cancer Res 2006; 4:15-25.
68. Le Cam L, Linares LK, Paul C et al. E4F1 is an atypical ubiquitin ligase that modulates p53 effector functions independently of degradation. Cell 2006; 127:775-88.
69. Kruse JP, Gu W. MSL2 promotes Mdm2-independent cytoplasmic localization of p53. J Biol Chem 2009; 284:3250-63.
70. Lee EW, Lee MS, Camus S et al. Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis. EMBO J 2009; 28:2100-13.
71. Wu X, Bayle JH, Olson D et al. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993; 7:1126-32.
72. Kawai H, Wiederschain D, Yuan ZM. Critical contribution of the MDM2 acidic domain to p53 ubiquitination. Mol Cell Biol 2003; 23:4939-47.
73. Meulmeester E, Frenk R, Stad R et al. Critical role for a central part of Mdm2 in the ubiquitylation of p53. Mol Cell Biol 2003; 23:4929-38.
74. Shvarts A, Steegenga WT, Riteco N et al. MDMX: a novel p53-binding protein with some functional properties ofMDM2. EMBO J 1996; 15:5349-57.
75. Marine JC, Jochemsen AG. Mdmx and Mdm2: brothers in arms? Cell Cycle 2004; 3:900-4.
76. Stad R, Ramos YF, Little N et al. Hdmx stabilizes Mdm2 and p53. J Biol Chem 2000; 275:28039-44.
77. Little NA, Jochemsen AG. Hdmx and Mdm2 can repress transcription activation by p53 but not by p63. Oncogene 2001; 20:4576-80.
78. Parant J, Chavez-Reyes A, Little NA et al. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet 2001; 29:92-5.
79. Finch RA, Donoviel DB, Potter D et al. mdmx is a negative regulator of p53 activity in vivo. Cancer Res 2002; 62:3221-5.
80. Migliorini D, Lazzerini Denchi E, Danovi D et al. Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol Cell Biol 2002; 22:5527-38.
81. Badciong JC, Haas AL. MdmX is a RING finger ubiquitin ligase capable of synergistically enhancing Mdm2 ubiquitination. J Biol Chem 2002; 277:49668-75.
82. Sharp DA, Kratowicz SA, Sank MJ et al. Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. J Biol Chem 1999; 274:38189-96.
83. Tanimura S, Ohtsuka S, Mitsui K et al. MDM2 interacts with MDMX through their RING finger domains. FEBS Lett 1999; 447:5-9.
84. Singh RK, Iyappan S, Scheffner M. Hetero-oligomerization with MdmX rescues the ubiquitin/Nedd8 ligase activity ofRING finger mutants ofMdm2. J Biol Chem 2007; 282:10901-7.
85. Stad R, Little NA, Xirodimas DP et al. Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms. EMBO Rep 2001; 2:1029-34.
86. Migliorini D, Danovi D, Colombo E et al. Hdmx recruitment into the nucleus by Hdm2 is essential for its ability to regulate p53 stability and transactivation. J Biol Chem 2002; 277:7318-23.
87. de Graaf P, Little NA, Ramos YF et al. Hdmx protein stability is regulated by the ubiquitin ligase activity ofMdm2. J Biol Chem 2003; 278:38315-24.
88. Pan Y, Chen J. MDM2 promotes ubiquitination and degradation of MDMX. Mol Cell Biol 2003; 23:5113-21.
89. Quelle DE, Zindy F, Ashmun RA et al. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83:993-1000.
90. Pomerantz J, Schreiber-Agus N, Liegeois NJ et al. The Ink4a tumor suppressor gene product, p19Arf interacts with MDM2 and neutralizes MDM2's inhibition ofp53. Cell 1998; 92:713-23.
91. Stott FJ, Bates S, James MC et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998; 17:5001-14.
92. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92:725-34.
93. Xirodimas D, Saville MK, Edling C et al. Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo. Oncogene 2001; 20:4972-83.
94. Lohrum MA, Ashcroft M, Kubbutat MH et al. Identification of a cryptic nucleolar-localization signal in MDM2. Nat Cell Biol 2000; 2:179-81.
95. Weber JD, Taylor LJ, Roussel MF et al. Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 1999; 1:20-6.
96. Zhang Y, Xiong Y. Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export ofMDM2 and p53. Mol Cell 1999; 3:579-91.
97. Tao W, Levine AJ. P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc Natl Acad Sci USA 1999; 96:6937-41.
98. Llanos S, Clark PA, Rowe J et al. Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus. Nat Cell Biol 2001; 3:445-52.
99. Honda R, Yasuda H. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity ofMdm2 for tumor suppressorp53. EMBO J 1999; 18:22-7.
100. Midgley Ca, Desterro JM, Saville MK et al. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene 2000; 19:2312-23.
101. Ringshausen I, O'Shea CC, Finch AJ et al. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 2006; 10:501-14.
102. Leng RP, Lin Y, Ma W et al. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell2003; 112:779-91.
103. Dornan D, Wertz I, Shimizu H et al. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 2004; 429:86-92.
104. Oliner JD, Kinzler KW, Meltzer PS et al. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358:80-3.
105. Leach FS, Tokino T, Meltzer P et al. p53 Mutation and MDM2 amplification inhuman soft tissue sarcomas. CancerRes 1993; 53:2231-4.
106. Dornan D, Bheddah S, Newton K et al. COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas. Cancer Res 2004; 64:7226-30.
107. Duan W, Gao L, Druhan LJ et al. Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer. J Natl Cancer Inst 2004; 96:1718-21.
108. Schwarz SE, Rosa JL, Scheffner M. Characterization of human hect domain family members and their interactionwithUbcH5 andUbcH7. JBiolChem 1998; 273:12148-54.
109. Chen D, Brooks CL, Gu W. ARF-BP1 as a potential therapeutic target. Br J Cancer 2006; 94:1555-8.
110. Chen D, Kon N, Li M et al. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 2005; 121:1071-83.
111. Zhong Q, Gao W, Du F et al. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiq-uitination ofMcl-1 andregulates apoptosis. Cell2005; 121:1085-95.
112. Adhikary S, Marinoni F, Hock A et al. The ubiquitin ligase HectH9 regulates transcriptional activation by Myc and is essential for tumor cell proliferation. Cell 2005; 123:409-21.
113. Rajendra R, Malegaonkar D, Pungaliya P et al. Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and ubiquitinates p53. J Biol Chem 2004; 279:36440-4.
114. Weger S, Hammer E, Heilbronn R. Topors acts as a SUMO-1 E3 ligase for p53 in vitro and in vivo. FEBS Lett 2005; 579:5007-12.
115. Yang X, Li H, Zhou Z et al. Plk1-mediated phosphorylation of Topors regulates p53 stability. J Biol Chem2009; 284:18588-92.
116. Yang W, Rozan LM, McDonald ER, 3rd et al. CARPs are ubiquitin ligases that promote MDM2-independent p53 and phospho-p53ser20 degradation. J Biol Chem 2007; 282:3273-81.
117. Yamasaki S, Yagishita N, Sasaki T et al. Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase 'Synoviolin'. EMBO J 2007; 26:113-22.
118. Xia Y, Padre RC, De Mendoza TH et al. Phosphorylation of p53 by IkappaB kinase 2 promotes its degradation by beta-TrCP. Proc Natl Acad Sci USA 2009; 106:2629-34.
119. Sun L, Shi L, Li W et al. JFK, a Kelch domain-containing F-box protein, links the SCF complex to p53 regulation. Proc Natl Acad Sci USA 2009; 106:10195-200.
120. Allton K, Jain AK, Herz HM et al. Trim24 targets endogenous p53 for degradation. Proc Natl Acad Sci USA2009; 106:11612-6.
121. Esser C, Scheffner M, Hohfeld J. The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation. J Biol Chem 2005; 280:27443-8.
122. Lukashchuk N, Vousden KH. Ubiquitination and degradation of mutant p53. Mol Cell Biol 2007; 27:8284-95.
123. Muller P, Hrstka R, Coomber D et al. Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene 2008; 27:3371-83.
124. Huibregtse JM, Scheffner M, Howley PM. Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Mol Cell Biol 1993; 13:775-84.
125. Scheffner M, Huibregtse JM, Vierstra RD et al. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993; 75:495-505.
126. Pan H, Griep AE. Altered cell cycle regulation in the lens of HPV-16 E6 or E7 transgenic mice: implications for tumor suppressor gene function in development. Genes Dev 1994; 8:1285-99.
127. Simonson SJ, Difilippantonio MJ, Lambert PF. Two distinct activities contribute to human papillomavirus 16 E6's oncogenic potential. Cancer Res 2005; 65:8266-73.
128. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2:342-50.
129. Beer-Romero P, Glass S, Rolfe M. Antisense targeting of E6AP elevates p53 in HPV-infected cells but not in normal cells. Oncogene 1997; 14:595-602.
130. Kim Y, Cairns MJ, Marouga R et al. E6AP gene suppression and characterization with in vitro selected hammerheadribozymes. Cancer Gene Ther 2003; 10:707-16.
131. Kelley ML, Keiger KE, Lee CJ et al. The global transcriptional effects of the human papillomavirus E6 protein in cervical carcinoma cell lines are mediated by the E6AP ubiquitin ligase. J Virol 2005; 79:3737-47.
132. Hengstermann A, D'Silva MA, Kuballa P et al. Growth suppression induced by downregulation of E6-AP expression in human papillomavirus-positive cancer cell lines depends on p53. J Virol 2005; 79:9296-300.
133. Querido E, Blanchette P, Yan Q et al. Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes Dev 2001; 15:3104-17.
134. Muller S, Dobner T. The adenovirus E1B-55K oncoprotein induces SUMO modification of p53. Cell Cycle 2008; 7:754-58.
135. Boutell C, Everett RD. The herpes simplex virus type 1 (HSV-1) regulatory protein ICP0 interacts with and Ubiquitinates p53. J Biol Chem 2003; 278:36596-602.
136. Holowaty MN, Zeghouf M, Wu H et al. Protein profiling with Epstein-Barr nuclear antigen-1 reveals an interaction with the herpesvirus-associated ubiquitin-specific protease HAUSP/USP7. J Biol Chem 2003; 278:29987-94.
137. Sato Y, Kamura T, Shirata N et al. Degradation of phosphorylated p53 by viral protein-ECS E3 ligase complex. PLoS Pathog 2009; 5:e1000530.
138. Cai QL, Knight JS, Verma SC et al. EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors. PLoS Pathog 2006; 2:e116.
139. Saha A, Murakami M, Kumar P et al. Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2. J Virol 2009; 83:4652-69.
140. Lee HR, TothZ, Shin YC et al. Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 4 targets MDM2 to deregulate the p53 tumor suppressor pathway. J Virol 2009; 83:6739-47.
141. Roth J, Dobbelstein M, Freedman DA et al. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J 1998; 17:554-64.
142. Stommel JM, Marchenko ND, Jimenez GS et al. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J 1999; 18:1660-72.
143. Tao W, Levine AJ. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation ofp53. Proc Natl Acad Sci USA 1999; 96:3077-80.
144. Boyd SD, Tsai KY, Jacks T. An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nat Cell Biol 2000; 2:563-8.
145. Li M, Brooks CL, Wu-Baer F et al. Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science 2003; 302:1972-5.
146. Brooks CL, GuW. p53 ubiquitination: Mdm2 andbeyond. Mol Cell2006; 21:307-15.
147. Carter S, Bischof O, Dejean A et al. C-terminal modifications regulate MDM2 dissociation and nuclear export ofp53. Nat Cell Biol 2007; 9:428-35.
148. Marchenko ND, Wolff S, Erster S et al. Monoubiquitylation promotes mitochondrial p53 translocation. EMBO J 2007; 26:923-34.
149. Zacchi P, Gostissa M, Uchida T et al. The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature 2002; 419:853-7.
150. Zheng H, You H, Zhou XZ et al. The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. Nature 2002; 419:849-53.
151. Siepe D, Jentsch S. Prolyl isomerase Pin1 acts as a switch to control the degree of substrate ubiquitylation. Nat Cell Biol 2009; 11:967-72.
152. Laine A, Topisirovic I, Zhai D et al. Regulation of p53 localization and activity by Ubc13. Mol Cell Biol 2006; 26:8901-13.
153. Topisirovic I, Gutierrez GJ, Chen M et al. Control of p53 multimerization by Ubc13 is JNK-regulated. Proc Natl Acad Sci USA 2009; 106:12676-81.
154. Laine A, RonaiZ. Regulation of p53 localization and transcription by the HECT domain E3 ligase WWP1. Oncogene 2007; 26:1477-83.
155. Stevenson LF, Sparks A, Allende-Vega N et al. The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. EMBO J 2007; 26:976-86.
156. Dayal S, Sparks A, Jacob J et al. Suppression of the deubiquitinating enzyme USP5 causes the accumulation of unanchored polyubiquitin and the activation of p53. J Biol Chem 2009; 284:5030-41.
157. Li M, Chen D, Shiloh A et al. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 2002; 416:648-53.
158. Li M, Brooks CL, Kon N et al. A dynamic role ofHAUSP in the p53-Mdm2 pathway. Mol Cell 2004; 13:879-86.
159. Yamaguchi T, Kimura J, Miki Y et al. The deubiquitinating enzyme USP11 controls an IkappaB kinase alpha (IKKalpha)-p53 signaling pathway in response to tumor necrosis factor alpha (TNFalpha). J Biol Chem 2007; 282:33943-8.
160. Zhang D, Zaugg K, Mak TW et al. A role for the deubiquitinating enzyme USP28 in control of the DNA-damage response. Cell 2006; 126:529-42.
161. Cummins JM, Rago C, Kohli M et al. Tumour suppression: disruption of HAUSP gene stabilizes p53. Nature 2004; 428:1 p following 486.
162. Tang J, Qu LK, Zhang J et al. Critical role for Daxx in regulating Mdm2. Nat Cell Biol 2006; 8:855-62.
163. Song MS, Song SJ, Kim SYet al. The tumour suppressor RASSF1A promotes MDM2 self-ubiquitination by disrupting the MDM2-DAXX-HAUSP complex. EMBO J 2008; 27:1863-74.
164. Meulmeester E, Maurice MM, Boutell C et al. Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization ofHdmx and Hdm2. Mol Cell 2005; 18:565-76.
165. Meulmeester E, Pereg Y, Shiloh Y et al. ATM-mediatedphosphorylations inhibit Mdmx/Mdm2 stabilization by HAUSP in favor ofp53 activation. Cell Cycle 2005; 4:1166-70.
166. Stommel JM, Wahl GM. Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBO J 2004; 23:1547-56.
167. Huang DT, Ayrault O, Hunt HW et al. E2-RING expansion of the NEDD8 cascade confers specificity to cullin modification. Mol Cell 2009; 33:483-95.
168. Pan ZQ, Kentsis A, Dias DC et al. Nedd8 on cullin: building an expressway to protein destruction. Oncogene 2004; 23:1985-97.
169. Xirodimas DP, Saville MK, Bourdon JC et al. Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 2004; 118:83-97.
170. Handeli S, Weintraub H. The ts41 mutation in Chinese hamster cells leads to successive S phases in the absence ofintervening G2, M and G1. Cell 1992; 71:599-611.
171. Abida WM, Nikolaev A, Zhao W et al. FBXO11 promotes the neddylation of p53 and inhibits its transcriptional activity. J Biol Chem 2006; 282:1797-804.
172. Geoffroy MC, Hay RT. An additional role for SUMO in ubiquitin-mediated proteolysis. Nat Rev Mol CellBiol2009; 10:564-8.
173. Gostissa M, Hengstermann A, Fogal Vet al. Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. EMBO J 1999; 18:6462-71.
174. Rodriguez MS, Desterro JM, Lain S et al. SUMO-1 modification activates the transcriptional response ofp53. EMBO J 1999; 18:6455-61.
175. Kahyo T, Nishida T, Yasuda H. Involvement of PIAS1 in the sumoylation of tumor suppressor p53. Mol Cell2001; 8:713-8.
176. Nelson V, Davis GE, Maxwell SA. A putative protein inhibitor of activated STAT (PIASy) interacts with p53 and inhibits p53-mediated transactivation but not apoptosis. Apoptosis 2001; 6:221-34.
177. Schmidt D, Muller S. Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity. Proc Natl Acad Sci USA 2002; 99:2872-7.
178. Bischof O, SchwambornK, MartinN et al. The E3 SUMO ligase PIASy is a regulator of cellular senescence and apoptosis. Mol Cell 2006; 22:783-94.
179. Wu SY, Chiang CM. Crosstalk between sumoylation and acetylation regulates p53-dependent chromatin transcription and DNA binding. EMBO J 2009; 28:1246-59.
180. Lee MH, Lee SW, Lee EJ et al. SUMO-specific protease SUSP4 positively regulates p53 by promoting Mdm2 self-ubiquitination. Nat Cell Biol 2006; 8:1424-31.
181. Yuan H, Zhou J, Deng M et al. Small ubiquitin-related modifier paralogs are indispensable but functionally redundant during early development of zebrafish. Cell Res 2009.
182. Zhang Y, Xiong Y. A p53 amino-terminal nuclear export signal inhibited by DNA damage-induced phosphorylation. Science 2001; 292:1910-5.
183. Shimizu H, Burch LR, Smith AJ et al. The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo. J Biol Chem 2002; 277:28446-58.